 "Ahmedabad-based Zydus Cadila got approval for conducting phase I/II trials for the 2019-nCoV vaccine 3mg")
A bunch of Covid-19 vaccine candidates got approval from the expert panel to conduct clinical trials in India, including one from Novavax, Bharat Biotech’s intra-nasal candidate, and a measles vector-based candidate from Zydus Cadila.
In its February 3 meeting, the subject expert panel (SEC) advising the Central Drugs Standard Control Organisation (CDSCO) recommended that approval be granted for conducting phase II/III clinical trials to Serum Institute of India (SII) for the Novavax candidate. This vaccine is based on protein nanoparticle and uses the proprietary Matrix-M adjuvant from Novavax. Adjuvants are pharmacological or immunological agents that improve the immune response
In its February 3 meeting, the subject expert panel (SEC) advising the Central Drugs Standard Control Organisation (CDSCO) recommended that approval be granted for conducting phase II/III clinical trials to Serum Institute of India (SII) for the Novavax candidate. This vaccine is based on protein nanoparticle and uses the proprietary Matrix-M adjuvant from Novavax. Adjuvants are pharmacological or immunological agents that improve the immune response
